+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Antibacterial Vaccines Market - Global Forecast 2026-2032- Product Image
Antibacterial Vaccines Market - Global Forecast 2026-2032- Product Image
Sale

Antibacterial Vaccines Market - Global Forecast 2026-2032

  • Report

  • 196 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6142362
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Antibacterial Vaccines Market is projected to reach USD 1.60 Billion in 2026. It is expected to continue growing at a CAGR of 10.22%, reaching USD 2.86 Billion by 2032.

Antibacterial Vaccines: Executive Summary

Antibacterial vaccines are preventive interventions designed to reduce the incidence, severity, transmission, or complications of bacterial disease. The landscape spans established immunization programs, vaccines for pathogens with substantial antimicrobial-resistance concerns, and candidates targeting infections where prevention could reduce reliance on antibiotics. Strategic relevance is shaped by public-health priorities, pathogen surveillance, clinical evidence, manufacturing capability, procurement systems, and confidence in vaccination.

Prevention Is Becoming Central to Antimicrobial-Resistance Strategy

The field is shifting from a narrow focus on childhood immunization toward broader life-course prevention, high-risk populations, and pathogens associated with difficult-to-treat infections. Public-health agencies increasingly assess vaccines alongside stewardship, diagnostics, infection prevention, sanitation, and surveillance. Development priorities are also being influenced by pathogen diversity, serotype or strain variation, durability of protection, safety requirements, and the practical challenges of demonstrating efficacy when disease incidence is uneven or declining.

Artificial Intelligence Accelerates Discovery, Surveillance, and Delivery Planning

Artificial intelligence can support antigen and epitope discovery, analysis of pathogen genomes, identification of correlates of protection, trial-site selection, and detection of safety or coverage gaps. Its value is cumulative when linked with laboratory, clinical, epidemiological, and immunization-record data. However, AI outputs require biological validation, representative datasets, transparent governance, cybersecurity controls, and regulatory scrutiny. Human oversight remains essential for decisions involving benefit-risk assessment, equitable access, and public communication.

Regional Priorities Differ by Disease Burden and Health-System Capacity

North America combines advanced research infrastructure with strong surveillance and regulatory capacity, while Latin America places particular emphasis on access, routine immunization resilience, and regionally relevant disease burdens. Europe benefits from coordinated public-health frameworks but must address cross-border procurement, aging populations, and confidence differences. The Middle East requires strategies suited to mobile populations, variable health-system capacity, and outbreak preparedness. Africa’s priorities include strengthening delivery systems, local evidence, financing, and supply reliability. Asia-Pacific presents wide variation, from highly developed immunization programs to settings where rural access, cold-chain capacity, and pathogen surveillance remain central challenges.

International Groups Shape Standards, Financing, and Deployment

ASEAN cooperation is relevant to regional surveillance, regulatory alignment, and access across diverse health systems. BRICS members can influence research collaboration, manufacturing capability, and technology transfer. The European Union supports coordinated assessment, procurement, and cross-border preparedness. G7 priorities emphasize antimicrobial resistance, innovation incentives, and resilient supply chains. GCC countries can contribute through well-resourced health systems, regional procurement, and preparedness initiatives. NATO’s relevance is concentrated in health security, operational readiness, biosurveillance, and continuity of medical supplies.

Country Contexts Reveal Distinct Implementation Priorities

Australia emphasizes evidence-based immunization policy, surveillance, and geographically inclusive delivery. Brazil’s priorities include broad public-program reach, local production capacity, and equitable access. Canada combines federal coordination with provincial delivery and attention to Indigenous and remote communities. China has substantial research, manufacturing, and public-health capabilities alongside the need for consistent confidence and access across regions. France, Germany, Italy, Spain, and the United Kingdom are shaped by European coordination, national immunization policy, aging populations, and antimicrobial-resistance programs. India’s scale makes affordability, delivery infrastructure, and locally relevant evidence especially important. Japan and South Korea bring strong health systems and advanced biomedical capabilities, with continued focus on aging-related risk and preparedness. Mexico faces the need to strengthen coverage continuity, surveillance, and access across diverse territories. Russia’s priorities include domestic capability, surveillance, and health-system resilience. The United States combines extensive research and regulatory capacity with attention to adult vaccination, antimicrobial resistance, procurement, and public confidence.

Industry Leaders Should Link Vaccine Innovation to Real-World Prevention

Organizations should prioritize pathogens and populations where prevention can produce clear clinical and stewardship benefits, while designing trials around meaningful outcomes and diverse settings. They should build partnerships with public-health agencies, hospitals, laboratories, manufacturers, and community organizations; plan for scalable production and temperature management early; and generate evidence on durability, co-administration, safety, and operational feasibility. Leaders should also use interoperable surveillance and carefully governed AI tools, prepare transparent risk communication, and align access strategies with the needs of lower-resource and geographically remote populations.

Methodology: Evidence-Led Assessment of the Antibacterial Vaccine Landscape

This executive summary uses a structured qualitative assessment of antibacterial-vaccine relevance across disease prevention, antimicrobial resistance, research and development, manufacturing, regulation, delivery, surveillance, and public confidence. Regional, group, and country perspectives are integrated according to documented differences in health-system capacity, immunization organization, demographic context, disease-prevention priorities, and preparedness needs. Interpretations should be validated against current guidance, peer-reviewed evidence, regulatory publications, surveillance data, and national immunization policies before operational decisions are made.

Conclusion: Prevention, Preparedness, and Access Must Advance Together

Antibacterial vaccines are increasingly viewed as part of a coordinated response to bacterial disease and antimicrobial resistance rather than as isolated products. Progress will depend on credible clinical evidence, pathogen-informed innovation, resilient manufacturing, effective delivery, responsible use of AI, and sustained public trust. The strongest strategies will connect regional and national priorities with equitable access, integrated surveillance, and measurable reductions in preventable disease and antibiotic dependence.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Antibacterial Vaccines Market, by Type
7.1. Introduction
7.2. Inactivated
7.3. Live Attenuated
7.4. Subunit
7.4.1. Conjugate
7.4.2. Polysaccharide
7.4.3. Protein Subunit
8. Antibacterial Vaccines Market, by Indication
8.1. Introduction
8.2. Meningococcal Disease
8.3. Pertussis
8.4. Pneumococcal Disease
8.5. Typhoid Fever
9. Antibacterial Vaccines Market, by Administration Route
9.1. Introduction
9.2. Intradermal
9.3. Intramuscular
9.4. Oral
9.5. Subcutaneous
10. Antibacterial Vaccines Market, by End User
10.1. Introduction
10.2. Clinics
10.3. Hospitals
11. Antibacterial Vaccines Market, by Distribution Channel
11.1. Introduction
11.2. Government Supply
11.3. Hospital Pharmacies
11.4. Online Pharmacies
11.5. Retail Pharmacies
12. Antibacterial Vaccines Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa
13. Antibacterial Vaccines Market, by Group
13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO
14. Antibacterial Vaccines Market, by Country
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. United Kingdom
14.7. Germany
14.8. France
14.9. Russia
14.10. Italy
14.11. Spain
14.12. China
14.13. India
14.14. Japan
14.15. Australia
14.16. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. AstraZeneca plc
16.2. Bharat Biotech International Limited
16.3. Biological E. Limited
16.4. CSL Limited
16.5. Emergent BioSolutions, Inc.
16.6. GlaxoSmithKline plc
16.7. Johnson & Johnson
16.8. Merck & Co., Inc.
16.9. Novartis AG
16.10. Panacea Biotec Ltd.
16.11. Pfizer Inc.
16.12. Sanofi Pasteur
16.13. Serum Institute of India Pvt. Ltd.
16.14. Sinovac Biotech Ltd.
16.15. Takeda Pharmaceutical Company Limited
16.16. Valneva SE
16.17. Wyeth Pharmaceuticals, Inc.
17. Key Experts
LIST OF FIGURES
FIGURE 1. Global Antibacterial Vaccines Market, Years Considered for the Study
FIGURE 2. Global Antibacterial Vaccines Market, Research Design
FIGURE 3. Global Antibacterial Vaccines Market, Research Framework
FIGURE 4. Global Antibacterial Vaccines Market, Data Triangulation
FIGURE 5. Global Antibacterial Vaccines Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Antibacterial Vaccines Market Size, by Type, 2025 vs 2032 (%)
FIGURE 7. Global Antibacterial Vaccines Market Size, by Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Antibacterial Vaccines Market Size, by Indication, 2025 vs 2032 (%)
FIGURE 9. Global Antibacterial Vaccines Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Antibacterial Vaccines Market Size, by Administration Route, 2025 vs 2032 (%)
FIGURE 11. Global Antibacterial Vaccines Market Size, by Administration Route, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Antibacterial Vaccines Market Size, by End User, 2025 vs 2032 (%)
FIGURE 13. Global Antibacterial Vaccines Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Antibacterial Vaccines Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 15. Global Antibacterial Vaccines Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Antibacterial Vaccines Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global Antibacterial Vaccines Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Antibacterial Vaccines Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Antibacterial Vaccines Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global Antibacterial Vaccines Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Antibacterial Vaccines Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Antibacterial Vaccines Market Segmentation & Coverage
TABLE 2. Global Antibacterial Vaccines Market Size, 2017-2032 (USD Million)
TABLE 3. Global Antibacterial Vaccines Market Size, by Type, 2017-2032 (USD Million)
TABLE 4. Global Inactivated Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Inactivated Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Inactivated Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Live Attenuated Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Live Attenuated Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Live Attenuated Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Subunit Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Subunit Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Subunit Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Conjugate Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Conjugate Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Conjugate Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Polysaccharide Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Polysaccharide Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Polysaccharide Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Protein Subunit Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Protein Subunit Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Protein Subunit Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Antibacterial Vaccines Market Size, by Indication, 2017-2032 (USD Million)
TABLE 23. Global Meningococcal Disease Market Size, by Region, 2017-2032 (USD Million)
TABLE 24. Global Meningococcal Disease Market Size, by Group, 2017-2032 (USD Million)
TABLE 25. Global Meningococcal Disease Market Size, by Country, 2017-2032 (USD Million)
TABLE 26. Global Pertussis Market Size, by Region, 2017-2032 (USD Million)
TABLE 27. Global Pertussis Market Size, by Group, 2017-2032 (USD Million)
TABLE 28. Global Pertussis Market Size, by Country, 2017-2032 (USD Million)
TABLE 29. Global Pneumococcal Disease Market Size, by Region, 2017-2032 (USD Million)
TABLE 30. Global Pneumococcal Disease Market Size, by Group, 2017-2032 (USD Million)
TABLE 31. Global Pneumococcal Disease Market Size, by Country, 2017-2032 (USD Million)
TABLE 32. Global Typhoid Fever Market Size, by Region, 2017-2032 (USD Million)
TABLE 33. Global Typhoid Fever Market Size, by Group, 2017-2032 (USD Million)
TABLE 34. Global Typhoid Fever Market Size, by Country, 2017-2032 (USD Million)
TABLE 35. Global Antibacterial Vaccines Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 36. Global Intradermal Market Size, by Region, 2017-2032 (USD Million)
TABLE 37. Global Intradermal Market Size, by Group, 2017-2032 (USD Million)
TABLE 38. Global Intradermal Market Size, by Country, 2017-2032 (USD Million)
TABLE 39. Global Intramuscular Market Size, by Region, 2017-2032 (USD Million)
TABLE 40. Global Intramuscular Market Size, by Group, 2017-2032 (USD Million)
TABLE 41. Global Intramuscular Market Size, by Country, 2017-2032 (USD Million)
TABLE 42. Global Oral Market Size, by Region, 2017-2032 (USD Million)
TABLE 43. Global Oral Market Size, by Group, 2017-2032 (USD Million)
TABLE 44. Global Oral Market Size, by Country, 2017-2032 (USD Million)
TABLE 45. Global Subcutaneous Market Size, by Region, 2017-2032 (USD Million)
TABLE 46. Global Subcutaneous Market Size, by Group, 2017-2032 (USD Million)
TABLE 47. Global Subcutaneous Market Size, by Country, 2017-2032 (USD Million)
TABLE 48. Global Antibacterial Vaccines Market Size, by End User, 2017-2032 (USD Million)
TABLE 49. Global Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 50. Global Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 51. Global Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 52. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 53. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 54. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 55. Global Antibacterial Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 56. Global Government Supply Market Size, by Region, 2017-2032 (USD Million)
TABLE 57. Global Government Supply Market Size, by Group, 2017-2032 (USD Million)
TABLE 58. Global Government Supply Market Size, by Country, 2017-2032 (USD Million)
TABLE 59. Global Hospital Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 60. Global Hospital Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 61. Global Hospital Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 62. Global Online Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 63. Global Online Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 64. Global Online Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 65. Global Retail Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 66. Global Retail Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 67. Global Retail Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 68. Global Antibacterial Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 69. Asia-Pacific Antibacterial Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 70. Asia-Pacific Antibacterial Vaccines Market Size, by Type, 2017-2032 (USD Million)
TABLE 71. Asia-Pacific Antibacterial Vaccines Market Size, by Subunit, 2017-2032 (USD Million)
TABLE 72. Asia-Pacific Antibacterial Vaccines Market Size, by Indication, 2017-2032 (USD Million)
TABLE 73. Asia-Pacific Antibacterial Vaccines Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 74. Asia-Pacific Antibacterial Vaccines Market Size, by End User, 2017-2032 (USD Million)
TABLE 75. Asia-Pacific Antibacterial Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 76. North America Antibacterial Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 77. North America Antibacterial Vaccines Market Size, by Type, 2017-2032 (USD Million)
TABLE 78. North America Antibacterial Vaccines Market Size, by Subunit, 2017-2032 (USD Million)
TABLE 79. North America Antibacterial Vaccines Market Size, by Indication, 2017-2032 (USD Million)
TABLE 80. North America Antibacterial Vaccines Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 81. North America Antibacterial Vaccines Market Size, by End User, 2017-2032 (USD Million)
TABLE 82. North America Antibacterial Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 83. Latin America Antibacterial Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 84. Latin America Antibacterial Vaccines Market Size, by Type, 2017-2032 (USD Million)
TABLE 85. Latin America Antibacterial Vaccines Market Size, by Subunit, 2017-2032 (USD Million)
TABLE 86. Latin America Antibacterial Vaccines Market Size, by Indication, 2017-2032 (USD Million)
TABLE 87. Latin America Antibacterial Vaccines Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 88. Latin America Antibacterial Vaccines Market Size, by End User, 2017-2032 (USD Million)
TABLE 89. Latin America Antibacterial Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 90. Europe Antibacterial Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 91. Europe Antibacterial Vaccines Market Size, by Type, 2017-2032 (USD Million)
TABLE 92. Europe Antibacterial Vaccines Market Size, by Subunit, 2017-2032 (USD Million)
TABLE 93. Europe Antibacterial Vaccines Market Size, by Indication, 2017-2032 (USD Million)
TABLE 94. Europe Antibacterial Vaccines Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 95. Europe Antibacterial Vaccines Market Size, by End User, 2017-2032 (USD Million)
TABLE 96. Europe Antibacterial Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 97. Middle East Antibacterial Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 98. Middle East Antibacterial Vaccines Market Size, by Type, 2017-2032 (USD Million)
TABLE 99. Middle East Antibacterial Vaccines Market Size, by Subunit, 2017-2032 (USD Million)
TABLE 100. Middle East Antibacterial Vaccines Market Size, by Indication, 2017-2032 (USD Million)
TABLE 101. Middle East Antibacterial Vaccines Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 102. Middle East Antibacterial Vaccines Market Size, by End User, 2017-2032 (USD Million)
TABLE 103. Middle East Antibacterial Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 104. Africa Antibacterial Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 105. Africa Antibacterial Vaccines Market Size, by Type, 2017-2032 (USD Million)
TABLE 106. Africa Antibacterial Vaccines Market Size, by Subunit, 2017-2032 (USD Million)
TABLE 107. Africa Antibacterial Vaccines Market Size, by Indication, 2017-2032 (USD Million)
TABLE 108. Africa Antibacterial Vaccines Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 109. Africa Antibacterial Vaccines Market Size, by End User, 2017-2032 (USD Million)
TABLE 110. Africa Antibacterial Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 111. Global Antibacterial Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 112. ASEAN Antibacterial Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 113. ASEAN Antibacterial Vaccines Market Size, by Type, 2017-2032 (USD Million)
TABLE 114. ASEAN Antibacterial Vaccines Market Size, by Subunit, 2017-2032 (USD Million)
TABLE 115. ASEAN Antibacterial Vaccines Market Size, by Indication, 2017-2032 (USD Million)
TABLE 116. ASEAN Antibacterial Vaccines Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 117. ASEAN Antibacterial Vaccines Market Size, by End User, 2017-2032 (USD Million)
TABLE 118. ASEAN Antibacterial Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 119. GCC Antibacterial Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 120. GCC Antibacterial Vaccines Market Size, by Type, 2017-2032 (USD Million)
TABLE 121. GCC Antibacterial Vaccines Market Size, by Subunit, 2017-2032 (USD Million)
TABLE 122. GCC Antibacterial Vaccines Market Size, by Indication, 2017-2032 (USD Million)
TABLE 123. GCC Antibacterial Vaccines Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 124. GCC Antibacterial Vaccines Market Size, by End User, 2017-2032 (USD Million)
TABLE 125. GCC Antibacterial Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 126. European Union Antibacterial Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 127. European Union Antibacterial Vaccines Market Size, by Type, 2017-2032 (USD Million)
TABLE 128. European Union Antibacterial Vaccines Market Size, by Subunit, 2017-2032 (USD Million)
TABLE 129. European Union Antibacterial Vaccines Market Size, by Indication, 2017-2032 (USD Million)
TABLE 130. European Union Antibacterial Vaccines Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 131. European Union Antibacterial Vaccines Market Size, by End User, 2017-2032 (USD Million)
TABLE 132. European Union Antibacterial Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 133. BRICS Antibacterial Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 134. BRICS Antibacterial Vaccines Market Size, by Type, 2017-2032 (USD Million)
TABLE 135. BRICS Antibacterial Vaccines Market Size, by Subunit, 2017-2032 (USD Million)
TABLE 136. BRICS Antibacterial Vaccines Market Size, by Indication, 2017-2032 (USD Million)
TABLE 137. BRICS Antibacterial Vaccines Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 138. BRICS Antibacterial Vaccines Market Size, by End User, 2017-2032 (USD Million)
TABLE 139. BRICS Antibacterial Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 140. G7 Antibacterial Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 141. G7 Antibacterial Vaccines Market Size, by Type, 2017-2032 (USD Million)
TABLE 142. G7 Antibacterial Vaccines Market Size, by Subunit, 2017-2032 (USD Million)
TABLE 143. G7 Antibacterial Vaccines Market Size, by Indication, 2017-2032 (USD Million)
TABLE 144. G7 Antibacterial Vaccines Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 145. G7 Antibacterial Vaccines Market Size, by End User, 2017-2032 (USD Million)
TABLE 146. G7 Antibacterial Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 147. NATO Antibacterial Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 148. NATO Antibacterial Vaccines Market Size, by Type, 2017-2032 (USD Million)
TABLE 149. NATO Antibacterial Vaccines Market Size, by Subunit, 2017-2032 (USD Million)
TABLE 150. NATO Antibacterial Vaccines Market Size, by Indication, 2017-2032 (USD Million)
TABLE 151. NATO Antibacterial Vaccines Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 152. NATO Antibacterial Vaccines Market Size, by End User, 2017-2032 (USD Million)
TABLE 153. NATO Antibacterial Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 154. Global Antibacterial Vaccines Market Size, by Country, 2017-2032 (USD Million)
TABLE 155. United States Antibacterial Vaccines Market Size, 2017-2032 (USD Million)
TABLE 156. United States Antibacterial Vaccines Market Size, by Type, 2017-2032 (USD Million)
TABLE 157. United States Antibacterial Vaccines Market Size, by Subunit, 2017-2032 (USD Million)
TABLE 158. United States Antibacterial Vaccines Market Size, by Indication, 2017-2032 (USD Million)
TABLE 159. United States Antibacterial Vaccines Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 160. United States Antibacterial Vaccines Market Size, by End User, 2017-2032 (USD Million)
TABLE 161. United States Antibacterial Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 162. Canada Antibacterial Vaccines Market Size, 2017-2032 (USD Million)
TABLE 163. Canada Antibacterial Vaccines Market Size, by Type, 2017-2032 (USD Million)
TABLE 164. Canada Antibacterial Vaccines Market Size, by Subunit, 2017-2032 (USD Million)
TABLE 165. Canada Antibacterial Vaccines Market Size, by Indication, 2017-2032 (USD Million)
TABLE 166. Canada Antibacterial Vaccines Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 167. Canada Antibacterial Vaccines Market Size, by End User, 2017-2032 (USD Million)
TABLE 168. Canada Antibacterial Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 169. Mexico Antibacterial Vaccines Market Size, 2017-2032 (USD Million)
TABLE 170. Mexico Antibacterial Vaccines Market Size, by Type, 2017-2032 (USD Million)
TABLE 171. Mexico Antibacterial Vaccines Market Size, by Subunit, 2017-2032 (USD Million)
TABLE 172. Mexico Antibacterial Vaccines Market Size, by Indication, 2017-2032 (USD Million)
TABLE 173. Mexico Antibacterial Vaccines Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 174. Mexico Antibacterial Vaccines Market Size, by End User, 2017-2032 (USD Million)
TABLE 175. Mexico Antibacterial Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 176. Brazil Antibacterial Vaccines Market Size, 2017-2032 (USD Million)
TABLE 177. Brazil Antibacterial Vaccines Market Size, by Type, 2017-2032 (USD Million)
TABLE 178. Brazil Antibacterial Vaccines Market Size, by Subunit, 2017-2032 (USD Million)
TABLE 179. Brazil Antibacterial Vaccines Market Size, by Indication, 2017-2032 (USD Million)
TABLE 180. Brazil Antibacterial Vaccines Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 181. Brazil Antibacterial Vaccines Market Size, by End User, 2017-2032 (USD Million)
TABLE 182. Brazil Antibacterial Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 183. United Kingdom Antibacterial Vaccines Market Size, 2017-2032 (USD Million)
TABLE 184. United Kingdom Antibacterial Vaccines Market Size, by Type, 2017-2032 (USD Million)
TABLE 185. United Kingdom Antibacterial Vaccines Market Size, by Subunit, 2017-2032 (USD Million)
TABLE 186. United Kingdom Antibacterial Vaccines Market Size, by Indication, 2017-2032 (USD Million)
TABLE 187. United Kingdom Antibacterial Vaccines Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 188. United Kingdom Antibacterial Vaccines Market Size, by End User, 2017-2032 (USD Million)
TABLE 189. United Kingdom Antibacterial Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 190. Germany Antibacterial Vaccines Market Size, 2017-2032 (USD Million)
TABLE 191. Germany Antibacterial Vaccines Market Size, by Type, 2017-2032 (USD Million)
TABLE 192. Germany Antibacterial Vaccines Market Size, by Subunit, 2017-2032 (USD Million)
TABLE 193. Germany Antibacterial Vaccines Market Size, by Indication, 2017-2032 (USD Million)
TABLE 194. Germany Antibacterial Vaccines Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 195. Germany Antibacterial Vaccines Market Size, by End User, 2017-2032 (USD Million)
TABLE 196. Germany Antibacterial Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 197. France Antibacterial Vaccines Market Size, 2017-2032 (USD Million)
TABLE 198. France Antibacterial Vaccines Market Size, by Type, 2017-2032 (USD Million)
TABLE 199. France Antibacterial Vaccines Market Size, by Subunit, 2017-2032 (USD Million)
TABLE 200. France Antibacterial Vaccines Market Size, by Indication, 2017-2032 (USD Million)
TABLE 201. France Antibacterial Vaccines Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 202. France Antibacterial Vaccines Market Size, by End User, 2017-2032 (USD Million)
TABLE 203. France Antibacterial Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 204. Russia Antibacterial Vaccines Market Size, 2017-2032 (USD Million)
TABLE 205. Russia Antibacterial Vaccines Market Size, by Type, 2017-2032 (USD Million)
TABLE 206. Russia Antibacterial Vaccines Market Size, by Subunit, 2017-2032 (USD Million)
TABLE 207. Russia Antibacterial Vaccines Market Size, by Indication, 2017-2032 (USD Million)
TABLE 208. Russia Antibacterial Vaccines Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 209. Russia Antibacterial Vaccines Market Size, by End User, 2017-2032 (USD Million)
TABLE 210. Russia Antibacterial Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 211. Italy Antibacterial Vaccines Market Size, 2017-2032 (USD Million)
TABLE 212. Italy Antibacterial Vaccines Market Size, by Type, 2017-2032 (USD Million)
TABLE 213. Italy Antibacterial Vaccines Market Size, by Subunit, 2017-2032 (USD Million)
TABLE 214. Italy Antibacterial Vaccines Market Size, by Indication, 2017-2032 (USD Million)
TABLE 215. Italy Antibacterial Vaccines Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 216. Italy Antibacterial Vaccines Market Size, by End User, 2017-2032 (USD Million)
TABLE 217. Italy Antibacterial Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 218. Spain Antibacterial Vaccines Market Size, 2017-2032 (USD Million)
TABLE 219. Spain Antibacterial Vaccines Market Size, by Type, 2017-2032 (USD Million)
TABLE 220. Spain Antibacterial Vaccines Market Size, by Subunit, 2017-2032 (USD Million)
TABLE 221. Spain Antibacterial Vaccines Market Size, by Indication, 2017-2032 (USD Million)
TABLE 222. Spain Antibacterial Vaccines Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 223. Spain Antibacterial Vaccines Market Size, by End User, 2017-2032 (USD Million)
TABLE 224. Spain Antibacterial Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 225. China Antibacterial Vaccines Market Size, 2017-2032 (USD Million)
TABLE 226. China Antibacterial Vaccines Market Size, by Type, 2017-2032 (USD Million)
TABLE 227. China Antibacterial Vaccines Market Size, by Subunit, 2017-2032 (USD Million)
TABLE 228. China Antibacterial Vaccines Market Size, by Indication, 2017-2032 (USD Million)
TABLE 229. China Antibacterial Vaccines Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 230. China Antibacterial Vaccines Market Size, by End User, 2017-2032 (USD Million)
TABLE 231. China Antibacterial Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 232. India Antibacterial Vaccines Market Size, 2017-2032 (USD Million)
TABLE 233. India Antibacterial Vaccines Market Size, by Type, 2017-2032 (USD Million)
TABLE 234. India Antibacterial Vaccines Market Size, by Subunit, 2017-2032 (USD Million)
TABLE 235. India Antibacterial Vaccines Market Size, by Indication, 2017-2032 (USD Million)
TABLE 236. India Antibacterial Vaccines Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 237. India Antibacterial Vaccines Market Size, by End User, 2017-2032 (USD Million)
TABLE 238. India Antibacterial Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 239. Japan Antibacterial Vaccines Market Size, 2017-2032 (USD Million)
TABLE 240. Japan Antibacterial Vaccines Market Size, by Type, 2017-2032 (USD Million)
TABLE 241. Japan Antibacterial Vaccines Market Size, by Subunit, 2017-2032 (USD Million)
TABLE 242. Japan Antibacterial Vaccines Market Size, by Indication, 2017-2032 (USD Million)
TABLE 243. Japan Antibacterial Vaccines Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 244. Japan Antibacterial Vaccines Market Size, by End User, 2017-2032 (USD Million)
TABLE 245. Japan Antibacterial Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 246. Australia Antibacterial Vaccines Market Size, 2017-2032 (USD Million)
TABLE 247. Australia Antibacterial Vaccines Market Size, by Type, 2017-2032 (USD Million)
TABLE 248. Australia Antibacterial Vaccines Market Size, by Subunit, 2017-2032 (USD Million)
TABLE 249. Australia Antibacterial Vaccines Market Size, by Indication, 2017-2032 (USD Million)
TABLE 250. Australia Antibacterial Vaccines Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 251. Australia Antibacterial Vaccines Market Size, by End User, 2017-2032 (USD Million)
TABLE 252. Australia Antibacterial Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 253. South Korea Antibacterial Vaccines Market Size, 2017-2032 (USD Million)
TABLE 254. South Korea Antibacterial Vaccines Market Size, by Type, 2017-2032 (USD Million)
TABLE 255. South Korea Antibacterial Vaccines Market Size, by Subunit, 2017-2032 (USD Million)
TABLE 256. South Korea Antibacterial Vaccines Market Size, by Indication, 2017-2032 (USD Million)
TABLE 257. South Korea Antibacterial Vaccines Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 258. South Korea Antibacterial Vaccines Market Size, by End User, 2017-2032 (USD Million)
TABLE 259. South Korea Antibacterial Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 260. Global Antibacterial Vaccines Market Share, by Key Player, 2025
TABLE 261. Global Antibacterial Vaccines Market, Key Experts

Companies Mentioned

  • AstraZeneca plc
  • Bharat Biotech International Limited
  • Biological E. Limited
  • CSL Limited
  • Emergent BioSolutions, Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Panacea Biotec Ltd.
  • Pfizer Inc.
  • Sanofi Pasteur
  • Serum Institute of India Pvt. Ltd.
  • Sinovac Biotech Ltd.
  • Takeda Pharmaceutical Company Limited
  • Valneva SE
  • Wyeth Pharmaceuticals, Inc.

Related Topics

Related Reports

Vaccines - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Vaccines - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Report
  • 100 Pages
  • Global
From
United States Vaccine Market Report and Forecast 2024-2032 - Product Image

United States Vaccine Market Report and Forecast 2024-2032

  • Report
  • 160 Pages
  • United States
From
North America Vaccines Market Outlook, 2028 - Product Image

North America Vaccines Market Outlook, 2028

  • Report
  • 101 Pages
  • North America
From
Vaccines Market - Global Forecast 2026-2032 - Product Image

Vaccines Market - Global Forecast 2026-2032

  • Report
  • 199 Pages
  • Global
From
Porcine Vaccine Market Report 2026 - Product Image

Porcine Vaccine Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.